## What is claimed is:

 A gene targeting construct, comprising a transgene encoding a polypeptide comprising a rod outer segment (ROS) targeting signal, said transgene flanked by 5' and 3' DNA sequences which are homologous to the mouse rhodopsin gene,

wherein homologous recombination between said construct and a mouse rhodopsin gene results in operable association between said transgene and a rod-specific regulatory sequence.

- 2. The construct of claim 1, wherein said polypeptide is a G protein-coupled receptor (GPCR).
- 3. The construct of claim 2, wherein said GPCR is a cannabinoid receptor.
- 15 4. The construct of claim 1, wherein said polypeptide is a fusion protein.
  - 5. The construct of claim 1, wherein said ROS targeting signal comprises SEQ ID NO:4.
- 6. The construct of claim 1, further 20 comprising a positive selection marker.
  - 7. The construct of claim 6, wherein said positive selection marker is a neomycin resistance gene.
  - 8. The construct of claim 6, wherein said positive selection marker is flanked by loxP sites.

- 9. The construct of claim 1, further comprising a negative selection marker.
- 10. The construct of claim 9, wherein said negative selection marker is a diphtheria toxin A fragment gene.
  - 11. The construct of claim 1, wherein said rod-specific regulatory sequence comprises a rhodopsin promoter.
- 12. The construct of claim 1, wherein the 5' flanking DNA sequence comprises a mouse rhodopsin promoter.
- 13. The construct of claim 1, wherein the 3' flanking sequence comprises a portion of exon 1 of mouse 15 rhodopsin.
  - 14. The construct of claim 1, wherein the 3' flanking sequence comprises exon 2 of mouse rhodopsin.
  - 15. A vector comprising the construct of claim 1.
- 20 16. A cell comprising the construct of claim 1.
  - 17. A mouse cell whose genome comprises:
  - a) a functional disruption of one or both endogenous rhodopsin gene alleles, and

- b) a transgene encoding a polypeptide
  comprising a ROS targeting signal operably associated
  with a rod-specific regulatory sequence,
  - wherein said polypeptide is not a rhodopsin.
- 5 18. The cell of claim 17, wherein said polypeptide is a GPCR.
  - \$19.\$ The cell of claim 18, wherein said GPCR is a cannabinoid receptor.  $^{\prime}$
- 20. The cell of claim 17, wherein said 10 polypeptide is a fusion protein.
  - 21. The cell of claim 17, wherein said ROS targeting signal comprises SEQ ID NO:4.
- 22. The cell of claim 17, wherein said genome comprises a functional disruption of both endogenous 15 rhodopsin gene alleles.
  - 23. The cell of claim 17, wherein said transgene is inserted into one or both endogenous rhodopsin gene alleles.
- 24. The cell of claim 17, which is an 20 embryonic stem cell.
  - 25. The cell of claim 17, which is in a mouse.
  - 26. The cell of claim 17, which is isolated from a mouse.

- 27. The cell of claim 26, which is a rod cell.
- 28. An extract of the cell of claim 27, comprising an outer segment membrane of said cell.
- 29. A substantially purified transgenic polypeptide comprising a ROS targeting signal, isolated from the rod cell of claim 27, or from an extract thereof.
  - 30. A mouse whose genome comprises:
- a) a functional disruption of one or both endogenous rhodopsin gene alleles, and
  - b) a transgene encoding a polypeptide comprising a ROS targeting signal operably associated with a rod-specific regulatory sequence,
- wherein said polypeptide is not a rhodopsin.
  - 31. The mouse of claim 30, wherein said polypeptide is a GPCR.
  - 32. The mouse of claim 31, wherein said GPCR is a cannabinoid receptor.
- 20 33. The mouse of claim 30, wherein said polypeptide is a fusion protein.
  - 34. The mouse of claim 30, wherein said ROS targeting signal comprises SEQ ID NO:4.
- 35. The mouse of claim 30, wherein said genome comprises a functional disruption of both endogenous rhodopsin gene alleles.

- 36. The mouse of claim 30, wherein said transgene is inserted into one or both endogenous rhodopsin gene alleles.
- 37. A rod cell or outer membrane extract5 thereof, isolated from the mouse of claim 30.
  - 38. A substantially purified transgenic polypeptide comprising a ROS targeting signal, isolated from the rod cell or extract of claim 37.